Latest News
Valtech Valuation Completes Impairment Testing for Plant and Machinery (Electric Vehicle Related) Assets
Valuation of Machinery & Equipment under IAS 36 Impairment of Assets Valtech Valuation is pleased to announce the successful completion of an impairment testing engagement on machinery and equipment related to electric vehicle (EV) technology. This project highlights Valtech’s
Strengthening Valuation Support for HKEx Notifiable Transactions
As regulatory scrutiny over corporate transactions continues to increase, robust and transparent valuation has become a critical component in supporting the basis of consideration for notifiable transactions of companies listed on the Hong Kong Exchanges and Clearing Limited.
Valtech Completed a Financial Guarantee Valuation for a Public Company
Financial guarantee arrangements are common within corporate groups, particularly when a parent or listed entity provides credit enhancement to enable subsidiaries or related parties to secure financing. However, such guarantees may give rise to financial reporting implications that require careful assessment and valuation.
Improve Valuation Quality for Financial Reporting in ECL
Valtech recently completed an engagement in Expected Credit Loss (ECL) assessment, assisting a client in enhancing its ECL assessment methodology, calculation process, and accounting disclosures. The client operates an international business distributing imported goods to both business customers and
Expected Credit Loss Evaluation by Jump Diffusion
Valtech, with strong academic foundations and deep expertise in accounting, finance, and quantitative modeling, is well positioned to provide robust valuation and advisory support for complex accounting matters that require advanced quantitative finance knowledge.
Valtech Valuation Completes Valuation of a Medical Company
Valtech’s valuation team has recently completed valuation in relation to a transaction of a medical company. The target company’s business is to develop IVD diagnostics products for various diseases. We are engaged to conduct purchase price allocation (PPA) and valuation of an additional investment option.